Cure trials expand as clinical AI and new drugs advance
LISTEN
Direct audio file (MP3)Global active cure-related trials now total 21,364, with 66 new wire signals and 40 new cure research items arriving in the last 24 hours. On the AI side, the clinical AI track is moving from talk to institutions: STAT+ reports Anthropic joining ARPA‑H’s “clinical AI moonshot,” alongside policy theater where a “Super Intelligence” executive order signals governance as the next lever. In therapeutics, retatrutide enters a phase 3 spotlight via TRIUMPH‑2, while AstraZeneca’s $2B investment in Summit Therapeutics points to continued capital commitment to targeted immunology. At the same time, perception and labor systems are being stress-tested by AI—an inversion of authorship in synthetic celebrity marketing and AI-generated resumes flooding hiring—reminding us that progress must be paired with human-proofing. The window is still open.
An executive order requires government use of “Super Intelligence” for AI.
Who gains is whoever can steer AI into governance and capital flow during the phase transition, while humanity benefits only if these capabilities accelerate cure research rather than slow it.
Watch whether clinical AI commitments (ARPA‑H/Anthropic) translate into publishable trial outputs fast enough to outrun the perception and adoption lag suggested by the wire.